Unknown

Dataset Information

0

Venetoclax, a BCL-2 Inhibitor, Enhances the Efficacy of Chemotherapeutic Agents in Wild-Type ABCG2-Overexpression-Mediated MDR Cancer Cells.


ABSTRACT: Previous studies have shown that small-molecule BCL-2 inhibitors can have a synergistic interaction with ABCG2 substrates in chemotherapy. Venetoclax is a potent and selective BCL-2 inhibitor, approved by the FDA in 2016 for the treatment of patients with chronic lymphocytic leukemia (CLL). This study showed that, at a non-toxic concentration, venetoclax at 10 µM significantly reversed multidrug resistance (MDR) mediated by wild-type ABCG2, without significantly affecting MDR mediated by mutated ABCG2 (R482G and R482T) and ABCB1, while moderate or no reversal effects were observed at lower concentrations (0.5 to 1 µM). The results showed that venetoclax increased the intracellular accumulation of chemotherapeutic agents, which was the result of directly blocking the wild-type ABCG2 efflux function and inhibiting the ATPase activity of ABCG2. Our study demonstrated that venetoclax potentiates the efficacy of wild-type ABCG2 substrate drugs. These findings may provide useful guidance in combination therapy against wild-type ABCG2-mediated MDR cancer in clinical practice.

SUBMITTER: Wang JQ 

PROVIDER: S-EPMC7072352 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Venetoclax, a BCL-2 Inhibitor, Enhances the Efficacy of Chemotherapeutic Agents in Wild-Type ABCG2-Overexpression-Mediated MDR Cancer Cells.

Wang Jing-Quan JQ   Li Jonathan Y JY   Teng Qiu-Xu QX   Lei Zi-Ning ZN   Ji Ning N   Cui Qingbin Q   Zeng Leli L   Pan Yihang Y   Yang Dong-Hua DH   Chen Zhe-Sheng ZS  

Cancers 20200218 2


Previous studies have shown that small-molecule BCL-2 inhibitors can have a synergistic interaction with ABCG2 substrates in chemotherapy. Venetoclax is a potent and selective BCL-2 inhibitor, approved by the FDA in 2016 for the treatment of patients with chronic lymphocytic leukemia (CLL). This study showed that, at a non-toxic concentration, venetoclax at 10 µM significantly reversed multidrug resistance (MDR) mediated by wild-type ABCG2, without significantly affecting MDR mediated by mutated  ...[more]

Similar Datasets

| S-EPMC4317847 | biostudies-other
| S-EPMC4686932 | biostudies-literature
| S-EPMC3548808 | biostudies-literature
| S-EPMC7471643 | biostudies-literature
| S-EPMC3546971 | biostudies-literature
| S-EPMC4245389 | biostudies-literature
| S-EPMC4924270 | biostudies-literature
| S-EPMC7005336 | biostudies-literature
| S-EPMC9138677 | biostudies-literature
| S-EPMC9255909 | biostudies-literature